Allogene Therapeutics Inc - Asset Resilience Ratio
Allogene Therapeutics Inc (ALLO) has an Asset Resilience Ratio of 48.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Allogene Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Allogene Therapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Allogene Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Allogene Therapeutics Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $214.38 Million | 48.75% |
| Total Liquid Assets | $214.38 Million | 48.75% |
Asset Resilience Insights
- Very High Liquidity: Allogene Therapeutics Inc maintains exceptional liquid asset reserves at 48.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Allogene Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Allogene Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Allogene Therapeutics Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Allogene Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 39.59% | $217.26 Million | $548.71 Million | -17.27pp |
| 2023-12-31 | 56.86% | $365.54 Million | $642.84 Million | +1.43pp |
| 2022-12-31 | 55.43% | $455.42 Million | $821.58 Million | +28.41pp |
| 2021-12-31 | 27.03% | $283.99 Million | $1.05 Billion | -25.47pp |
| 2020-12-31 | 52.50% | $644.56 Million | $1.23 Billion | +2.98pp |
| 2019-12-31 | 49.51% | $355.41 Million | $717.80 Million | +2.09pp |
| 2018-12-31 | 47.42% | $366.95 Million | $773.86 Million | -- |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more